ACTIDIET-PRO Study: Evaluating Lifestyle Intervention on Metastatic Prostate Cancer Patients

Strategic Insights -

Chris O'Brien Lifehouse has launched the ACTIDIET-PRO study, a clinical trial to assess the effects of a lifestyle intervention on physical activity and diet in patients with metastatic prostate cancer receiving novel hormonal agents. The study aims to evaluate the feasibility of an exercise and diet intervention in Australian men with metastatic hormone-resistant prostate cancer. The trial is led by Prof Lisa Horvath, with the registration number ACTRN12625000784415.

Key Takeaways:

  • The ACTIDIET-PRO study is a 12-week lifestyle intervention program for patients with metastatic prostate cancer, focusing on intensified physical activity and a controlled dietary regimen.
  • Participants will undergo two supervised exercise sessions and one pre-instructed home-session per week, including cardio and resistance training.
  • The dietary regimen will consist of a balanced diet with low total fat, low saturated fat, high omega-3 fatty acids, optimized protein content, and low simple carbohydrates.
  • The study aims to assess changes in prostate-specific antigen (PSA), quality of life, fatigue, lipid, and immune signatures through serial blood profiling.
  • The study's primary goal is to understand whether benefits from diet and exercise prescribed in men with early-stage prostate cancer can be replicated in those with advanced-stage disease.
  • Participants will be eligible if they are aged 18 or older, have been diagnosed with adenocarcinoma of the prostate, and are receiving ongoing treatment with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI).
  • Prof Lisa Horvath is the principal investigator of the clinical trial, and the study type is Interventional.

Statistics:

  • The study will involve a 12-week lifestyle intervention program.
  • Participants will undergo 3 exercise sessions per week, including 2 supervised sessions and 1 pre-instructed home-session.
  • The dietary regimen will consist of a balanced diet.
  • The study aims to assess changes in PSA, quality of life, fatigue, lipid, and immune signatures through serial blood profiling.
  • Participants must have a rising PSA with no evidence of clinical or radiographic progression on imaging evaluation.

Sources:

  • Australian New Zealand Clinical Trials Registry (ANZCTR)